Leigh Brody

Director/Miembro de la Junta en Bloomsbury Genetic Therapies Ltd. .

Consumer Services

Finance

Health Technology

Perfil

Leigh Brody is currently the Director at Bloomsbury Genetic Therapies Ltd.
and Investment Manager at Albion Capital Group LLP.
Brody holds a doctorate degree from Imperial College London and an undergraduate degree from Simmons University.

Cargos activos de Leigh Brody

Empresas	Cargo	Inicio
Albion Capital Group LLP Albion Capital Group LLP Investment ManagersFinance Albion Ventures LLP (Albion Ventures) is a venture capital firm founded in 1996. The firm is headquartered in London.	Inversor de Capital Privado	01/01/2021
Bloomsbury Genetic Therapies Ltd. Bloomsbury Genetic Therapies Ltd. BiotechnologyHealth Technology Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021.	Director/Miembro de la Junta	01/04/2022

Todos los cargos activos de Leigh Brody

Formación de Leigh Brody.

Simmons University	Undergraduate Degree
Imperial College London	Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Leigh Brody.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Albion Capital Group LLP Albion Capital Group LLP Investment ManagersFinance Albion Ventures LLP (Albion Ventures) is a venture capital firm founded in 1996. The firm is headquartered in London.	Finance
Bloomsbury Genetic Therapies Ltd. Bloomsbury Genetic Therapies Ltd. BiotechnologyHealth Technology Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021.	Health Technology